Share this article on:

Pediatric Suppurative Parotitis in Cambodia Between 2007 and 2011

Stoesser, Nicole MB BS*†‡; Pocock, Joanna MB BChir†§¶; Moore, Catrin E. DPhil*†‡; Soeng, Sona*; Chhat, Hor P.*; Sar, Poda*; Limmathurotsakul, Direk MD, PhD; Day, Nicholas FRCP, PhD†‡; Thy, Vann MD*; Sar, Vuthy MD*; Parry, Christopher M. FRCPath, PhD*†‡


Regarding the article on page 865, volume 31, issue 8 of The Pediatric Infectious Disease Journal the authors would like to correct the following:

There was an error with respect to the susceptibility results of Burkholderia pseudomallei strains isolated as part of this study. All 28 strains available for analysis were in fact susceptible to co-trimoxazole (disk zone >16mm; if zone ≤16mm, result by E-test ≤2mg/L). Co-trimoxazole would therefore be a reasonable alternative to co-amoxiclav as consolidation/eradication therapy in Cambodian children pending the results of local susceptibility testing.

The Pediatric Infectious Disease Journal. 32(7):e290, July 2013.

The Pediatric Infectious Disease Journal: August 2012 - Volume 31 - Issue 8 - p 865–868
doi: 10.1097/INF.0b013e318258873b
Brief Reports

The causes of suppurative parotitis in Cambodian children are not known. We describe 39 cases at the Angkor Hospital for Children, Siem Reap, between January 2007 and July 2011 (0.07/1000 hospital attendances). The median age was 5.7 years with no neonates affected. Burkholderia pseudomallei was cultured in 29 (74%) cases. No deaths occurred; 1 child developed facial nerve palsy.

From the *Angkor Hospital for Children, Siem Reap, Cambodia; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford University, Oxford; §Department of Medicine, Addenbrooke’s Hospital, Cambridge; University of Cambridge, Cambridge, United Kingdom.

Accepted for publication April 2, 2012.

Supported by the Wellcome Trust of Great Britain and the Li Ka Shing-University of Oxford Global Health Program. The authors have no other funding or conflicts of interest to disclose.

Address for Correspondence: Nicole Stoesser, MB BS, Microbiology Laboratory, Angkor Hospital for Children, Vithey Preah Sangreach Tep Vong & Um Chhay St, Sangkat Svay Dangkum Commune, Siem Reap, Cambodia. E-mail:

© 2012 Lippincott Williams & Wilkins, Inc.